

## Drug Prior Authorization Form Botox (onabotulinumtoxinA)

The purpose of this form is to obtain information required to assess your drug claim.

IMPORTANT: Please answer all questions. Your claim assessment will be delayed if this form is incomplete or contains errors.

# Any costs incurred for the completion of this form are the responsibility of the plan member/patient.

Canada Life recognizes and respects the importance of privacy. Personal information collected is used for the purposes of assessing eligibility for this drug and for administering the group benefits plan. For a copy of our Privacy Guidelines, or if you have questions about Canada Life's personal information policies and practices (including with respect to service providers), refer to <u>www.canadalife.com</u> or write to Canada Life's Chief Compliance Officer.

I authorize Canada Life, any healthcare provider, my plan administrator, any insurance or reinsurance company, administrators of government benefits or patient assistance programs or other benefits programs, other organizations, or service providers working with these purposes. I understand that personal information may be subject to disclosure to those authorized under applicable law within or outside Canada.

I acknowledge that the personal information is needed to assess eligibility for this drug and to administer the group benefits plan. I acknowledge that providing consent will help Canada Life to assess my claim and that refusing to consent may result in delay or denial of my claim. Canada Life reserves the right to audit the information provided on this form at any time and this consent extends to any audit of my claim. This consent may be revoked by me at any time by sending written instruction to that effect.

I also consent to the use of my personal information for Canada Life and its affiliates' internal data management and analytics purposes.

If the patient is a person other than myself, I confirm that the patient has given their consent to provide their personal information and for Canada Life to use and disclose it as set out above.

I certify that the information given below is true, correct, and complete to the best of my knowledge. Failure to provide true, correct and complete information on this form could result in revocation of any approval decision, a requirement to repay paid claims or other appropriate action.

Plan Member's signature: \_\_

Date: \_\_\_\_\_

### Form Completion Instructions:

- 1. Complete "Patient Information" sections.
- 2. Have the prescribing physician complete the "Physician Information" sections.
- 3. Send all pages of the completed form to us by mail, fax or email as noted below.

Note: As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

Mail to: The Canada Life Assurance Company Drug Claims Management PO Box 6000 Winnipeg MB R3C 3A5 Fax to: The Canada Life Assurance Company Fax 1-204-946-7664 Attention: Drug Claims Management

Email to: cldrug\_services@canadalife.com Attention: Drug Claims Management

For additional information regarding Prior Authorization and Health Case Management, please visit our Canada Life website at <u>www.canadalife.com</u> or contact Group Customer Contact Services at 1-800-957-9777. Deaf or hard of hearing and require access to a telecommunications relay service? Please contact us at 711 for TTY to Voice or 1-800-855-0511 for Voice to TTY.

(Continued on next page)

© The Canada Life Assurance Company, all rights reserved. Canada Life and design are trademarks of The Canada Life Assurance Company. Any modification of this document without the express written consent of Canada Life is strictly prohibited.



## Patient Information Botox (onabotulinumtoxinA)

Plan Member Information - Comp	lete all sections of	this page (please	print)		
Plan Member:		Patient Name:	Patient Name:		
Plan Name:	Plan Number:		Plan Member ID Number:		
Patient Date of Birth (DD/MM/YYYY):	Address (number, st	Address (number, street, city, province, postal code):			
Please indicate preferred contact number an	nd if there are any times wh	hen telephone contact v	with you about your claim would be most convenient.		
May we contact you by email? (Note that so Yes No If yes, please provide en		still need to be sent by r	regular mail).		
Tell us if you have been on this d	rug before				
Is the patient currently on, or previously be If Yes, a) indicate start date (DD/MM/YYYY b) coverage provided by: (if coverage is not provided by Cana	):		g purchase of this drug)		
Tell us if you have coverage with	any other benefits p	alan			
Does the patient have drug coverage unde If Yes, name of other Insurance Company. If other plan is with Canada Life, tell us the Name of plan member:	plan and iD number:				
Tell us about any Provincial or ot	her coverage you ma	<b>ay have</b>			
Does the patient have coverage under a pr	ovincial program or from a	ny other source? 🗌 Y	es 🗍 No		
If Yes, name of program or other source:					
Provide details and attach documentation is the patient currently receiving disability to			an amouther? Ver No		
		A STATE OF THE STA			
Tell us about any Patient Assista	nce Program you mi	ght be enrolled in	and the second		
Has the patient enrolled in the patient assis		ıg? □Yes □No			
If Yes, please provide the following informa					
1. Patient assistance program patient II					
<ol> <li>Patient assistance program contact p</li> </ol>	erson name and phone nu				
Contact Name:		Phone Numbe	är		



## Physician Information Botox (onabotulinumtoxinA)

# Note to Physician: In order to assess a patient's claim for this drug, we require detailed information on the patient's prescription drug history as requested below.

### Attach extra information if necessary. GENETIC TEST RESULTS ARE NOT REQUIRED

Physician's Information (please print)				
Name of prescribing physician:				
Specialty:				
Address (number, street, city, province, postal code):				
Telephone Number (including area code):	Fax Number (including area code):			
1. Prescribed dose and regimen:				
2. Health Canada Indication (include date of initial	diagnosis) (MM/YYYY):			
Bladder Dysfunction				
Blepharospasm	□ Focal Spasticity			
Cervical Dystonia/Spasmodic Torticollis				
Chronic Migraines	Strabismus			
Complete questions 1 - 7 and Physician's inform	nation			
Other (approved by Health Canada):				
Complete questions 1 - 7 and Other condition (F	fealth Canada approved)			
$\Box$ Other (prescribed use is not approved by Hea	ith Canada):			
Complete questions 1 - 7 and Off-label use				
3. What is the anticipated duration of treatment with	h this drug?			
4. Where will treatment be administered?	e Physician's Office Private clinic Hospital in-patient Hospital out-patient			
5. Please provide medical rationale why Botox has	been prescribed instead of an alternate drug in the same therapeutic class:			
6. Has the patient been referred to any specialists for	or their condition? 🗌 Yes 🔲 No			

Name of Physician	Specialty	Date of Referral (DD/MM/YYYY)



## Physician Information Botox (onabotulinumtoxinA)

# Physician's Information (continued) (please print)

# 7. Drug and Treatment History – must be completed for every request. INCLUDE APPLICABLE PRESCRIPTION AND NON-PRESCIPTION

THERAPIES.				
Drug(s) and Treatment(s) past and present	Dosing Regimen	Start Date (DD/MM/YYYY)	End Date (DD/MM/YYYY)	Clinical Results/Outcome
				Failure Intolerance Other Clinical details:
				☐ Failure ☐ Intolerance ☐ Other Clinical details:
				Failure I intolerance Other Clinical details:
Bladder Dysfunction				
		and and a final sector of the sector of the	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
Overactive Bladder				
Patient has failed a trial of anticho	blinergic medications.	Yes 🗌 No		
Uninary incontinence due to Ne	urogenic Detrusor Over	activity (NDO)		
Patient has been diagnosed with	one of the follow:			
Multiple Sclerosis				
Subcervical spinal cord injury				
Patient has failed a trial of anticho	olinergic medications.	Yes 🗌 No		
Blepharospasm	ta participation		Lands	
Does this patient have any of the	following conditions?			
Benign essential blepharosp				
Dystonia (movement disorde				
VII nerve disorders	Yes No			
Cervical Dystonia (spasm	odic torticollis)	1. 1. 24.		
Other causes of patients sympton	ns have been investigate	d and ruled out. 🗌 Y	íes 🗌 No	
Chronic Migraines			and the second	
Does the patient have ≥15 migrai		ache lasting 4 hours a	a day or longer?	Yes 🗌 No
Date of most recent migraine (DD	/MM/YYYY):			
Patient has had a three-month tri	al of at least one prophyla	actic treatment for ch	ronic migraine head	taches. Li Yes Li No
Dynamic Equinus Foot				and a second sec

Patient's dynamic equinus foot is due to spasticity of pediatric cerebral palsy. Is the intent of treatment to improve range of motion at a joint affected by a fixed contracture? Yes No



### Physician's Information (continued) (please print)

#### **Focal Spasticity**

Is the intent of treatment to improve the range of motion at a joint affected by a fixed contracture? \_\_\_ Yes \_\_ No

### Hyperhidrosis of the Axillae

Patient has failed a trial of 'clinical strength' antiperspirant (e.g. 20-25% aluminum chloride).

#### Strabismus

Does the patient have any of the following conditions?

Restrictive strabismus Yes No

Duane's syndrome with lateral rectal weakness \_\_\_\_ Yes \_\_\_ No

Secondary strabismus caused by prior surgical over-recession of antagonist \_\_\_\_ Yes \_\_\_ No

If yes; Botox is being used to reduce antagonist contracture in conjunction with surgical repair. 🗌 Yes 🗌 No

## Other condition (Health Canada approved)

Please provide any relevant information related to the disease and attach supporting documentation.

#### **Off-label use**

Questions 1 - 7 must be completed.

Is there clinical evidence supporting the off-label use of this drug? Yes No

Provide clinical literature/studies to support the request for off-label use, such as:

- · At least two Phase II or two Phase III clinical trials showing consistent results of efficacy; and
- · Published recommendations in evidence-based guidelines supporting its use.

Provide medical rationale why Botox has been prescribed off-label instead of an alternate drug with an approved indication for this condition.

Provide any pertinent medical history or information to support this off-label request.

If this is a renewal request, provide documentation showing treatment efficacy since previous request.



## Physician Information Botox (onabotulinumtoxinA)

Note for Physician: To be eligible for reimbursement, Canada Life may require your patient to purchase a drug requiring prior authorization from a pharmacy designated by Canada Life. If applicable, a health case manager will contact you with further information.

I certify that the information provided is true, correct, and complete.

Physician's Signature:	Date:

License Number: \_

It is important to provide the requested information in detail to help avoid delay in assessing claims for the above drug. This form may be subject to audit. The completed form can be returned to Canada Life by mail, fax, or email.

Note: As email is not a secure medium, any person with concerns about their prior authorization form/medical information being intercepted by an unauthorized party is encouraged to submit their form by other means.

Mail to: The Canada Life Assurance Company Drug Claims Management PO Box 6000 Winnipeg MB R3C 3A5 Fax to: The Canada Life Assurance Company Fax 1-204-946-7664 Attention: Drug Claims Management

Email to: cldrug.services@canadalife.com Attention: Drug Claims Management

